This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of +2.52% and +1.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Pediatrix Medical Group (MD) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Select Medical Expands Presence in Tennessee With Ballad Health Deal
by Zacks Equity Research
SEM partners with Ballad Health to relocate and expand its Tri-Cities critical illness recovery hospital, boosting care access in Tennessee by being able to treat more patients grappling with serious illnesses.
MD or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?
Why Pediatrix Medical Group (MD) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MD or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?
Pediatrix Medical Group (MD) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
by Zacks Equity Research
MD rises 5.6% YTD as earnings beat, hospital deals and lower costs drive growth. The Zacks Rank #2 signals strong near-term prospects.
Wall Street Analysts See a 26.4% Upside in Pediatrix Medical Group (MD): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Pediatrix Medical Group (MD) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Investors Should Consider Retaining Danaher Stock Now
by Zacks Equity Research
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
MD vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pediatrix Medical Group (MD) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Pediatrix Medical Group (MD) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs
by Zacks Equity Research
MD anticipates adjusted EBITDA to be between $220 million and $240 million in 2025.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Pediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 32% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MD vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?
Can Lower Expenses Save Pediatrix Medical's Q1 Earnings?
by Zacks Equity Research
MD's first-quarter results are likely to reflect declining hospital contract administrative fees.
Zacks.com featured highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander
by Zacks Equity Research
Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander have been highlighted in this Screen of The Week article.
Boost Your Portfolio With These 5 Low Price-to-Book Stocks
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.
Here's Why Pediatrix Medical Group (MD) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MD or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?